结直肠癌(colorectal cancer，CRC)是我国常见的消化道恶性肿瘤。大量研究证实，肠道菌群紊乱可通过多种机制促进CRC的发生、发展，以调节肠道菌群为目的的治疗方式可能对辅助治疗CRC有一定的效果，但仍存在局限性和不良反应。有研究表明，采用基因编辑工程菌与基因编辑直接改造肠道细菌2种方式治疗CRC，具有潜在的临床应用价值。本文通过梳理现阶段基因编辑肠道细菌治疗CRC的相关研究进展，探讨了未来基因编辑肠道细菌治疗CRC的可能性。

Colorectal cancer (CRC) is a common digestive malignant tumor in China. A large number of studies have confirmed that intestinal flora disorders can promote the occurrence and development of CRC through a variety of mechanisms, and regulating intestinal flora can exert certain auxiliary therapeutic effects on CRC. But the treatment still has certain limitations and side effects. Studies have shown that the clinical treatment of CRC by engineered and edited intestinal bacteria through gene editing may have potential application values. In this paper, the current research progress on gene-editing for modifying intestinal bacteria in the treatment of CRC is reviewed, aiming to explore the possibility of gene-edited intestinal bacteria in the treatment of CRC in the future.